Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.
- 2025 royalty income from DAYBUE® grew 15% to A$65 million
- Strong cash reserves of A$296 million support ongoing R&D
- Phase 3 'Koala' trial for NNZ-2591 in Phelan-McDermid syndrome underway
- Acadia’s DAYBUE STIX powder formulation launched in US, boosting growth prospects
- On-market share buy-back initiated to address market undervaluation
Profitability driven by DAYBUE® royalties and strong cash flow
Neuren Pharmaceuticals Limited (ASX:NEU) closed 2025 with a net profit after tax of A$30.4 million, a significant achievement given the absence of one-time milestone revenues that buoyed the prior year. The boost came largely from a 15% increase in royalty income from DAYBUE® (trofinetide), which reached A$65 million for the year. This growth was underpinned by a record US$391 million in net sales of DAYBUE, including a milestone quarter in Q4 with over 1,000 unique patients treated. The company’s cash position strengthened to A$296 million, providing ample runway for ongoing development and corporate initiatives.
Phase 3 trial for NNZ-2591 kicks off with community support
Neuren is advancing its NNZ-2591 (ercanetide) program, targeting multiple rare neurodevelopmental disorders. The highlight is the initiation of the pivotal Phase 3 "Koala" trial in Phelan-McDermid syndrome (PMS), a rare genetic condition with no approved treatments. The trial, enrolling approximately 160 children aged 3 to 12, is designed as a randomized, double-blind, placebo-controlled study evaluating safety and efficacy over 13 weeks, followed by an open-label extension. Encouraging Phase 2 data showed significant improvements in communication and global symptom assessments, bolstering confidence in the program. The FDA has granted Fast Track and Rare Pediatric Disease designations for NNZ-2591 in PMS, enhancing regulatory support and potential market exclusivity.
DAYBUE STIX launch and international regulatory efforts
Acadia Pharmaceuticals, Neuren’s exclusive licensee for trofinetide, launched DAYBUE STIX, a preservative-free powder formulation, in the US in early 2026. This new option aims to capture patients who declined or discontinued the liquid formulation, potentially unlocking up to 400 additional patients. Early caregiver feedback has been positive, reflecting the formulation’s convenience and palatability. Meanwhile, Acadia is pursuing marketing authorisation in Europe, having requested a re-examination of a negative EMA decision, with a potential outcome expected by mid-2026. A small clinical trial in Japan is underway to support a marketing application, with results anticipated by late 2026 or early 2027. These regulatory efforts underpin the company’s long-term growth strategy for DAYBUE beyond the US market, complementing the strong domestic sales momentum. This follows the recent DAYBUE royalties hit record where Neuren reported robust 2025 royalties and 2026 guidance.
Share buy-back signals confidence amid market undervaluation
In a notable capital management move, Neuren launched an on-market share buy-back program in early 2026, citing a material undervaluation of its assets relative to internal and broker models. Supported by a strong cash balance and growing DAYBUE royalties, the buy-back aims to enhance shareholder value without compromising funding for NNZ-2591 development. The program allows repurchase of up to 5% of shares over 12 months, reflecting management’s conviction in the company’s pipeline and commercial prospects.
Financial discipline amid rising R&D and corporate costs
Neuren’s operating expenses rose moderately in 2025, with R&D spend increasing to A$36.4 million, primarily due to Phase 3 trial start-up costs for NNZ-2591. Corporate and administrative expenses also climbed to A$6.2 million, driven by higher share-based payments linked to new option grants. Despite these cost increases, the company generated positive operating cash flow of A$125.4 million, reflecting strong royalty receipts and disciplined cash management. Foreign currency fluctuations contributed an A$8 million gain, partly offsetting derivative losses. The net profit and cash flow profile position Neuren well for sustained investment in clinical programs.
Governance, ESG, and patient-centric focus
Neuren maintains a lean, home-based workforce with zero Scope 1 and 2 emissions, aligning with its ESG commitments. The company emphasizes collaboration with patient advocacy groups and ethical clinical practices, including adherence to Good Clinical Practice standards and responsible animal research policies. Its board and executive team bring deep pharmaceutical and biotech experience, overseeing a governance framework tailored to the company’s size and development stage. Neuren’s strategy prioritizes orphan drug indications with high unmet need and regulatory incentives, aiming to deliver meaningful benefits to patients and shareholders alike.
Bottom Line?
Neuren’s robust 2025 results and advancing NNZ-2591 pipeline set a foundation for value creation, but clinical and regulatory milestones in 2026 will be pivotal.
Questions in the middle?
- How will the EMA re-examination outcome for trofinetide influence European market access and Neuren’s valuation?
- What enrolment pace and interim data from the Koala Phase 3 trial could signal early success or challenges?
- Could the share buy-back program shift investor sentiment or liquidity dynamics in the near term?